Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (721-730 of 1,058) with videos related to

Pageof 106
Sort By:
Oncotarget|April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemiaTimothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.
Leukemia|May 16, 2019
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignanciesKerry A Rogers, Luay Mousa, Qiuhong Zhao, et al.
Blood|November 21, 2012
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBo Yu, Yicheng Mao, Li-Yuan Bai, et al.
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Molecular Pharmaceutics|February 3, 2009
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2Xiaojuan Yang, Chee Guan Koh, Shujun Liu, et al.
Blood|April 19, 2007
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalXiaobin Zhao, Rosa Lapalombella, Trupti Joshi, et al.
Pageof 106

Showing results (721-730 of 1,058) with videos related to

Sort By:
Pageof 106
Oncotarget|April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemiaTimothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 7, 2025
Feasibility of Bruton's Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient PerspectiveDeborah M Stephens, Chris Stewart, Liza Avruch, et al.
Blood|July 27, 2021
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinibAdam S Kittai, Cecelia Miller, Daniel Goldstein, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
JAMA Oncology|February 23, 2018
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical TrialsSusan M O'Brien, Samantha Jaglowski, John C Byrd, et al.
Leukemia|May 16, 2019
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignanciesKerry A Rogers, Luay Mousa, Qiuhong Zhao, et al.
Blood|November 21, 2012
Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemiaBo Yu, Yicheng Mao, Li-Yuan Bai, et al.
Blood|August 2, 2022
Ventricular arrhythmias and sudden death events following acalabrutinib initiationSeema A Bhat, John Gambril, Leylah Azali, et al.
Molecular Pharmaceutics|February 3, 2009
Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2Xiaojuan Yang, Chee Guan Koh, Shujun Liu, et al.
Blood|April 19, 2007
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalXiaobin Zhao, Rosa Lapalombella, Trupti Joshi, et al.
Pageof 106